RELIANT trial underway
This article was originally published in The Gray Sheet
Executive Summary
FDA clearance of IDE permits first 50 patients to be enrolled in U.S. trial comparing WorldHeart'sNovacor left-ventricular assist system with Thoratec's HeartMate XVE.The full trial, intended to support a PMA supplement for Novacor as a destination therapy in transplant-ineligible patients, will enroll 225 patients in up to 40 centers, pending further review by FDA. HeartMate is the only LVAD approved for destination therapy in the U.S. (1"The Gray Sheet" Nov. 10, 2003, p. 39)...
You may also be interested in...
WorldHeart Changes LVAD Development Plan, Cites Medicare Trial Coverage
WorldHeart likely will abandon efforts to earn FDA supplemental approval for the Novacor left-ventricular assist device as destination therapy based on results from the INTrEPID trial
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.